Triazole Carboxamide Derivatives for Selective TAAR1 Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medications targeting central nervous system disorders often have undesirable side effects due to non-selective binding to adrenergic receptors, and there is a need for compounds that selectively target trace amine associated receptors (TAARs), particularly TAAR1, to treat various psychiatric and neurological conditions.
Innovation Solution
Development of compounds of formula I, which are triazole derivatives with specific substituents, exhibiting high affinity for TAAR1 and selectivity over adrenergic receptors, allowing for their use in treating depression, anxiety disorders, Parkinson's disease, ADHD, and other conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If compounds are designed to target adrenergic receptors for treating central nervous system disorders, then therapeutic effects are achieved, but undesirable side effects occur due to non-selective binding
Solution Approach 1:
The patent applies local quality by designing compounds with specific substituent patterns at defined positions (R1-R6) to achieve selective binding to TAAR1 receptor while avoiding adrenergic receptors. The triazole core with specific substituent configurations creates localized interaction characteristics that differentiate TAAR1 binding from adrenergic receptor binding, thereby achieving therapeutic efficacy without the harmful side effects associated with non-selective adrenergic binding.
2Object-affected harmful factors
If compounds are designed to achieve high selectivity for TAAR1 over adrenergic receptors, then side effects are reduced, but compound structure complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the compound structure into distinct functional modules: a triazole core structure and multiple substitutable positions (R1-R6) that can be independently optimized. This modular approach allows systematic development of selective TAAR1 ligands by varying substituents at specific positions, achieving high selectivity without requiring overly complex molecular structures.
Data Source
AI summary
The invention relates to compounds of formula (I), wherein R1 is phenyl or pyridinyl, optionally substituted by halogen, lower alkyl, lower alkoxy, lower alkyl substituted by halogen and lower alkoxy substituted by halogen; X1 is -N= or CH; X2 is CR2 or =N-; X3 is -N= or CH; with the proviso that only two of X1, X2 or X3 are nitrogen; wherein is a triazole group, selected from R2 is hydrogen or lower alkyl; Z is a bond, -O- or -CH2-; or to pharmaceutically suitable acid addition salts thereof. It has now been found that the compounds of formulas I have a good affinity to the trace amine associated receptors (TAARs), especially for TAAR1. The compounds may be used for the treatment of depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder (ADHD), stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders.